No abstract available
Keywords:
hepatic malignancy; magnetic resonance imaging; steatotic liver disease.
PubMed Disclaimer
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
-
-
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi‐society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):S0168‐8278(23)00418‐X. Online ahead of print. PMID: 37364790. 10.1016/j.jhep.2023.06.003
-
DOI
-
PubMed
-
-
Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, et al. Liver imaging reporting and data system (LI‐RADS) version 2018: imaging of hepatocellular carcinoma in at‐risk patients. Radiology. 2018;289(3):816–830. 10.1148/radiol.2018181494
-
DOI
-
PMC
-
PubMed
-
-
Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. Epub 2018 Apr 5. Erratum in: J Hepatol. 2019 Apr;70(4):817. PMID: 29628281. 10.1016/j.jhep.2018.03.019
-
DOI
-
PubMed
-
-
Toh WS, Chan KS, Ding CSL, Tan CH, Shelat VG. Intrahepatic splenosis: a world review. Clin Exp Hepatol. 2020;6(3):185–198. Epub 2020 Sep 30. PMID: 33145425; PMCID: PMC7592095. 10.5114/ceh.2020.99509
-
DOI
-
PMC
-
PubMed